{"transactions":[{"id":3921,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-04T00:26:18.000Z","date":"2026-09-01","kind":"exercise","planned":false,"acquired":false,"shares":5144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":8.15,"expiration_date":"2026-09-26","underlying":"Common Shares","underlying_shares":5144},"source":{"system":"sec-edgar","filing":"0001193125-26-382412","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526382412/ownership.xml","form_type":"4"}},{"id":3920,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-04T00:26:18.000Z","date":"2026-09-01","kind":"exercise","planned":false,"acquired":true,"shares":5144,"price":8.15,"value":41923.6,"ownership":{"direct":true},"balance_after":31373,"source":{"system":"sec-edgar","filing":"0001193125-26-382412","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526382412/ownership.xml","form_type":"4"}},{"id":750919,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-06-04T01:03:24.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":1593,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."}],"balance_after":1593,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":1593},"source":{"system":"sec-edgar","filing":"0001193125-26-256118","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000119312526256118/ownership.xml","form_type":"4"}},{"id":750918,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-06-04T01:03:24.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":10507,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."}],"balance_after":10507,"derivative":{"exercise_price":53.46,"expiration_date":"2036-06-02","underlying":"Common Shares","underlying_shares":10507},"source":{"system":"sec-edgar","filing":"0001193125-26-256118","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000119312526256118/ownership.xml","form_type":"4"}},{"id":750917,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-06-04T01:03:24.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":false,"shares":2645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":2645},"source":{"system":"sec-edgar","filing":"0001193125-26-256118","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000119312526256118/ownership.xml","form_type":"4"}},{"id":750916,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-04T01:03:24.000Z","date":"2026-06-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1416,"price":53.41,"value":75628.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of Common Shares withheld by the issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of the RSUs, and does not represent a sale."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the closing price of Common Shares on June 1, 2026 for purposes of net settlement calculations."}],"balance_after":26229,"source":{"system":"sec-edgar","filing":"0001193125-26-256118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000119312526256118/ownership.xml","form_type":"4"}},{"id":750915,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-04T01:03:24.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":true,"shares":2645,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":27645,"source":{"system":"sec-edgar","filing":"0001193125-26-256118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000119312526256118/ownership.xml","form_type":"4"}},{"id":974110,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T13:31:45.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10450,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option granted under a Company Equity Plan having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that was outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, and in exchange for such cancellation, the holder of such Cash-Out Stock Option received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option granted under a Company Equity Plan having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that was outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, and in exchange for such cancellation, the holder of such Cash-Out Stock Option received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option granted under a Company Equity Plan having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that was outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, and in exchange for such cancellation, the holder of such Cash-Out Stock Option received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":2.32,"underlying":"Common Stock","underlying_shares":10450},"source":{"system":"sec-edgar","filing":"0001574579-25-000004","document":"form4-12102025_061241.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000157457925000004/form4-12102025_061241.xml","form_type":"4"}},{"id":974109,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T13:31:45.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10520,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":7.32,"underlying":"Common Stock","underlying_shares":10520},"source":{"system":"sec-edgar","filing":"0001574579-25-000004","document":"form4-12102025_061241.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000157457925000004/form4-12102025_061241.xml","form_type":"4"}},{"id":974108,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T13:31:45.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":15.6,"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001574579-25-000004","document":"form4-12102025_061241.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000157457925000004/form4-12102025_061241.xml","form_type":"4"}},{"id":974107,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T13:31:45.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":9.9,"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001574579-25-000004","document":"form4-12102025_061241.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000157457925000004/form4-12102025_061241.xml","form_type":"4"}},{"id":974106,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T13:31:45.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":37,"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001574579-25-000004","document":"form4-12102025_061241.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000157457925000004/form4-12102025_061241.xml","form_type":"4"}},{"id":974105,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T13:31:45.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":128.2,"underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001574579-25-000004","document":"form4-12102025_061241.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000157457925000004/form4-12102025_061241.xml","form_type":"4"}},{"id":974104,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T13:31:45.000Z","date":"2025-12-09","kind":"other","planned":false,"acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the \"CVR Agreement\") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the \"CVR Agreement\") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001574579-25-000004","document":"form4-12102025_061241.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000157457925000004/form4-12102025_061241.xml","form_type":"4"}},{"id":1104685,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T16:24:23.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":10450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable on the earlier of June 17, 2026 or the 2026 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":10450,"derivative":{"exercise_price":2.32,"expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":10450},"source":{"system":"sec-edgar","filing":"0001415889-25-017850","document":"form4-06202025_080619.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000141588925017850/form4-06202025_080619.xml","form_type":"4"}},{"id":1119191,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2025-06-06T21:57:25.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":2645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":2645,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":2645},"source":{"system":"sec-edgar","filing":"0000950170-25-083317","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000095017025083317/ownership.xml","form_type":"4"}},{"id":1119190,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-06-06T21:57:25.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":17012,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":17012,"derivative":{"exercise_price":30.73,"expiration_date":"2035-06-04","underlying":"Common Shares","underlying_shares":17012},"source":{"system":"sec-edgar","filing":"0000950170-25-083317","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000095017025083317/ownership.xml","form_type":"4"}},{"id":1134807,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-23T20:06:02.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":155450,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48 of the shares subject to the option vested on January 1, 2023 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":0,"derivative":{"exercise_price":5.8766,"expiration_date":"2032-11-30","underlying":"Common Stock","underlying_shares":155450},"source":{"system":"sec-edgar","filing":"0001962918-25-000054","document":"wk-form4_1748030755.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000196291825000054/wk-form4_1748030755.xml","form_type":"4"}},{"id":1134806,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-23T20:06:02.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23243,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":0,"derivative":{"exercise_price":18,"expiration_date":"2033-05-03","underlying":"Common Stock","underlying_shares":23243},"source":{"system":"sec-edgar","filing":"0001962918-25-000054","document":"wk-form4_1748030755.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000196291825000054/wk-form4_1748030755.xml","form_type":"4"}},{"id":1134805,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-23T20:06:02.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":92158,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":0,"derivative":{"exercise_price":4.46,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":92158},"source":{"system":"sec-edgar","filing":"0001962918-25-000054","document":"wk-form4_1748030755.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000196291825000054/wk-form4_1748030755.xml","form_type":"4"}},{"id":1134804,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-23T20:06:02.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the \"Merger Agreement\") with Alumis, Inc., a Delaware corporation (\"Parent\"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the \"Merger\"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the \"Exchange Ratio\") shares of voting common stock of Parent, par value $0.0001 per share (\"Parent Common Stock\"), and cash in lieu of any fractional shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001962918-25-000054","document":"wk-form4_1748030755.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000196291825000054/wk-form4_1748030755.xml","form_type":"4"}},{"id":1472856,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-20T16:47:26.000Z","date":"2024-06-17","kind":"grant","planned":false,"acquired":true,"shares":10520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable on the earlier of June 17, 2025 or the 2025 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":10520,"derivative":{"exercise_price":7.32,"expiration_date":"2034-06-16","underlying":"Common Stock","underlying_shares":10520},"source":{"system":"sec-edgar","filing":"0001415889-24-017677","document":"form4-06202024_080622.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000141588924017677/form4-06202024_080622.xml","form_type":"4"}},{"id":1483016,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2024-06-11T23:07:33.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":92158,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":92158,"derivative":{"exercise_price":4.46,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":92158},"source":{"system":"sec-edgar","filing":"0001962918-24-000087","document":"wk-form4_1718147244.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000196291824000087/wk-form4_1718147244.xml","form_type":"4"}},{"id":1489486,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-05T21:41:36.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":15542,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 100% on the earlier of (i) June 4, 2025 or (ii) the day before the date of the issuer's 2025 annual meeting of shareholders."}],"balance_after":15542,"derivative":{"exercise_price":38.16,"expiration_date":"2034-06-04","underlying":"Common Shares","underlying_shares":15542},"source":{"system":"sec-edgar","filing":"0000950170-24-069462","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000095017024069462/ownership.xml","form_type":"4"}},{"id":1797420,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-08-24T20:33:47.000Z","date":"2023-08-24","kind":"sale","planned":false,"acquired":false,"shares":25000,"price":38.7,"value":967500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.70 to $38.79, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0000950170-23-044403","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000095017023044403/ownership.xml","form_type":"4"}},{"id":1856942,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-13T17:10:57.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 9, 2024 or the 2024 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.56,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-23-036813","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000120919123036813/doc4.xml","form_type":"4"}},{"id":1869106,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-02T21:24:20.000Z","date":"2023-06-02","kind":"grant","planned":false,"acquired":true,"shares":18475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 100% on the earlier of (i) June 1, 2024 or (ii) the day immediately preceding the day of the following year's annual meeting."}],"balance_after":18475,"derivative":{"exercise_price":38.96,"expiration_date":"2033-06-01","underlying":"Common Shares","underlying_shares":18475},"source":{"system":"sec-edgar","filing":"0000950170-23-026178","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000095017023026178/ownership.xml","form_type":"4"}},{"id":1896386,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2023-05-12T01:11:46.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":true,"shares":23243,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."}],"balance_after":23243,"derivative":{"exercise_price":18,"expiration_date":"2033-05-03","underlying":"Common Stock","underlying_shares":23243},"source":{"system":"sec-edgar","filing":"0001209191-23-028882","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000120919123028882/doc4.xml","form_type":"4"}},{"id":1896385,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2023-05-12T01:11:46.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":false,"shares":23243,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."}],"balance_after":0,"derivative":{"exercise_price":18,"expiration_date":"2033-05-03","underlying":"Class A Common Stock","underlying_shares":23243},"source":{"system":"sec-edgar","filing":"0001209191-23-028882","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000120919123028882/doc4.xml","form_type":"4"}},{"id":1896384,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2023-05-12T01:11:46.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":true,"shares":155450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48 of the shares subject to the option vested on January 1, 2023 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."}],"balance_after":155450,"derivative":{"exercise_price":5.8766,"expiration_date":"2032-11-30","underlying":"Common Stock","underlying_shares":155450},"source":{"system":"sec-edgar","filing":"0001209191-23-028882","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000120919123028882/doc4.xml","form_type":"4"}},{"id":1896383,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2023-05-12T01:11:46.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":false,"shares":155450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48 of the shares subject to the option vested on January 1, 2023 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."}],"balance_after":0,"derivative":{"exercise_price":5.8766,"expiration_date":"2032-11-30","underlying":"Class A Common Stock","underlying_shares":155450},"source":{"system":"sec-edgar","filing":"0001209191-23-028882","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000120919123028882/doc4.xml","form_type":"4"}},{"id":1896382,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-12T01:11:46.000Z","date":"2023-05-09","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":18,"value":270000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares purchased through a directed share program in the Issuer's initial public offering of Common Stock (the \"IPO\")."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-23-028882","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000120919123028882/doc4.xml","form_type":"4"}},{"id":1904049,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2023-05-05T00:24:49.000Z","date":"2023-05-04","kind":"grant","planned":false,"acquired":true,"shares":23243,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each share of Class A Common Stock shall be reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock."}],"balance_after":23243,"derivative":{"exercise_price":18,"expiration_date":"2033-05-03","underlying":"Class A Common","underlying_shares":23243},"source":{"system":"sec-edgar","filing":"0001209191-23-027539","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000120919123027539/doc4.xml","form_type":"4"}},{"id":2141448,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T20:20:35.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":5600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":22.3,"underlying":"Common Stock","underlying_shares":5600},"source":{"system":"sec-edgar","filing":"0000899243-22-033157","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924322033157/doc4.xml","form_type":"4"}},{"id":2141447,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T20:20:35.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":5600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":37.09,"underlying":"Common Stock","underlying_shares":5600},"source":{"system":"sec-edgar","filing":"0000899243-22-033157","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924322033157/doc4.xml","form_type":"4"}},{"id":2141446,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T20:20:35.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":5247,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":64.75,"underlying":"Common Stock","underlying_shares":5247},"source":{"system":"sec-edgar","filing":"0000899243-22-033157","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924322033157/doc4.xml","form_type":"4"}},{"id":2141445,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T20:20:35.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":56.3,"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000899243-22-033157","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924322033157/doc4.xml","form_type":"4"}},{"id":2141444,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T20:20:35.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":38.68,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-22-033157","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924322033157/doc4.xml","form_type":"4"}},{"id":2141443,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-10-06T20:20:35.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":3600,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit of the Issuer (\"RSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3600},"source":{"system":"sec-edgar","filing":"0000899243-22-033157","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924322033157/doc4.xml","form_type":"4"}},{"id":2141442,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-06T20:20:35.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":5376,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation (\"Parent\"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of the effective time of the Merger (the \"Effective Time\") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share (\"Common Stock\"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the \"Merger Consideration\"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-033157","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924322033157/doc4.xml","form_type":"4"}},{"id":2219189,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-29T21:44:29.000Z","date":"2022-06-28","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the common shares subject to the option will vest on the earlier of (i) the first anniversary of grant date and (ii) the day immediately preceding the day of the Issuer's next annual general meeting of shareholders."}],"balance_after":18000,"derivative":{"exercise_price":30.11,"expiration_date":"2032-06-27","underlying":"Common Shares","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-22-039836","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000120919122039836/doc4.xml","form_type":"4"}},{"id":2223776,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-22T22:00:11.000Z","date":"2022-06-21","kind":"sale","acquired":false,"shares":1908,"price":27.2446,"value":51982.6968,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2022 to cover the Reporting Person's tax obligations in connection with the vesting of 3,600 shares of Common Stock underlying the Reporting Person's RSUs as previously reported on the Form 4 filed by the Reporting Person on June 16, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $26.80 to $27.69 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":5376,"source":{"system":"sec-edgar","filing":"0000899243-22-023597","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924322023597/doc4.xml","form_type":"4"}},{"id":2229523,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-06-16T22:00:56.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":3600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":3600,"derivative":{"underlying":"Common Stock","underlying_shares":3600},"source":{"system":"sec-edgar","filing":"0000899243-22-022889","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924322022889/doc4.xml","form_type":"4"}},{"id":2229522,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-16T22:00:56.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":5600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 14, 2022 for 11 months and the remaining 1/12th on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":5600,"derivative":{"exercise_price":22.3,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":5600},"source":{"system":"sec-edgar","filing":"0000899243-22-022889","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924322022889/doc4.xml","form_type":"4"}},{"id":2229521,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-06-16T22:00:56.000Z","date":"2022-06-14","kind":"exercise","acquired":false,"shares":3600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vested in a single installment on June 14, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vested in a single installment on June 14, 2022."}],"balance_after":0,"derivative":{"exercise_date":"2022-06-14","underlying":"Common Stock","underlying_shares":3600},"source":{"system":"sec-edgar","filing":"0000899243-22-022889","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924322022889/doc4.xml","form_type":"4"}},{"id":2229520,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-16T22:00:56.000Z","date":"2022-06-14","kind":"exercise","acquired":true,"shares":3600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":7284,"source":{"system":"sec-edgar","filing":"0000899243-22-022889","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924322022889/doc4.xml","form_type":"4"}},{"id":2232310,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-14T16:22:48.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 10, 2023 or the 2023 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":40000,"derivative":{"exercise_price":0.9903,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-22-036690","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000120919122036690/doc4.xml","form_type":"4"}},{"id":2236569,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-10T20:06:01.000Z","date":"2022-06-09","kind":"sale","acquired":false,"shares":738,"price":27.201,"value":20074.338,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,333 RSUs from a January 7, 2022 grant of 3,200 RSUs."}],"balance_after":29017,"source":{"system":"sec-edgar","filing":"0001415889-22-006410","document":"form4-06102022_010651.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588922006410/form4-06102022_010651.xml","form_type":"4"}},{"id":2265274,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-18T16:43:52.000Z","date":"2022-05-16","kind":"purchase","acquired":true,"shares":30000,"price":0.8526,"value":25578.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $0.8402 to $0.8538. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001209191-22-030075","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000120919122030075/doc4.xml","form_type":"4"}},{"id":2438155,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right To Buy)","published_at":"2022-01-11T21:14:30.000Z","date":"2022-01-07","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on January 7, 2022 and vests over one year in twelve equal monthly installments, commencing on February 7, 2022."}],"balance_after":12000,"derivative":{"exercise_price":38.1,"expiration_date":"2032-01-06","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001179110-22-000392","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000117911022000392/edgar.xml","form_type":"4"}},{"id":2438154,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T21:14:30.000Z","date":"2022-01-07","kind":"grant","acquired":true,"shares":3200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Restricted stock units granted on January 7, 2022 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 8, 2022 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 7, 2023."}],"balance_after":29755,"source":{"system":"sec-edgar","filing":"0001179110-22-000392","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000117911022000392/edgar.xml","form_type":"4"}},{"id":2438153,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T21:14:30.000Z","date":"2022-01-07","kind":"sale","acquired":false,"shares":510,"price":38.525,"value":19647.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 963 RSUs from a January 6, 2021 grant of 1,650 RSUs."}],"balance_after":26555,"source":{"system":"sec-edgar","filing":"0001179110-22-000392","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000117911022000392/edgar.xml","form_type":"4"}},{"id":2660134,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-06-21T20:31:30.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":3600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":3600,"derivative":{"underlying":"Common Stock","underlying_shares":3600},"source":{"system":"sec-edgar","filing":"0000899243-21-025001","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924321025001/doc4.xml","form_type":"4"}},{"id":2660133,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-21T20:31:30.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":5600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 17, 2021 for 11 months and the remaining 1/12th on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":5600,"derivative":{"exercise_price":37.09,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":5600},"source":{"system":"sec-edgar","filing":"0000899243-21-025001","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924321025001/doc4.xml","form_type":"4"}},{"id":2660132,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-06-21T20:31:30.000Z","date":"2021-06-17","kind":"exercise","acquired":false,"shares":3037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vested in a single installment on June 17, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vested in a single installment on June 17, 2021."}],"balance_after":0,"derivative":{"exercise_date":"2021-06-17","underlying":"Common Stock","underlying_shares":3037},"source":{"system":"sec-edgar","filing":"0000899243-21-025001","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924321025001/doc4.xml","form_type":"4"}},{"id":2660131,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-21T20:31:30.000Z","date":"2021-06-18","kind":"sale","acquired":false,"shares":1609,"price":36.54,"value":58792.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2021 to cover the Reporting Person's tax obligations in connection with the vesting of 3,037 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":3684,"source":{"system":"sec-edgar","filing":"0000899243-21-025001","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924321025001/doc4.xml","form_type":"4"}},{"id":2660130,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-21T20:31:30.000Z","date":"2021-06-17","kind":"exercise","acquired":true,"shares":3037,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":5293,"source":{"system":"sec-edgar","filing":"0000899243-21-025001","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924321025001/doc4.xml","form_type":"4"}},{"id":2672535,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-11T20:47:21.000Z","date":"2021-06-09","kind":"sale","acquired":false,"shares":365,"price":41.885,"value":15288.025,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 687 RSUs from a January 6, 2021 grant of 1,650 RSUs."}],"balance_after":27065,"source":{"system":"sec-edgar","filing":"0001179110-21-006598","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000117911021006598/edgar.xml","form_type":"4"}},{"id":2682371,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T01:16:00.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to\nthe Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year\nanniversary of the grant date."}],"balance_after":10000,"derivative":{"exercise_price":18.56,"expiration_date":"2031-06-02","underlying":"Common Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-038079","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000120919121038079/doc4.xml","form_type":"4"}},{"id":2711958,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-14T20:04:11.000Z","date":"2021-05-12","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of May 12, 2022 or the 2022 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":40000,"derivative":{"exercise_price":3.7,"expiration_date":"2031-05-11","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-032961","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000120919121032961/doc4.xml","form_type":"4"}},{"id":2763456,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-01T20:21:42.000Z","date":"2021-03-31","kind":"purchase","acquired":true,"shares":20000,"price":10.0169,"value":200338.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $9.936 to $10.0599. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001209191-21-024310","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000120919121024310/doc4.xml","form_type":"4"}},{"id":2886602,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-02T23:18:19.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":506,"price":56.956,"value":28819.736,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 963 RSUs from a January 29, 2020 grant of 1,650 RSUs."}],"balance_after":27430,"source":{"system":"sec-edgar","filing":"0001179110-21-001091","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000117911021001091/edgar.xml","form_type":"4"}},{"id":2912636,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right To Buy)","published_at":"2021-01-08T22:09:36.000Z","date":"2021-01-06","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 6, 2021 and vests over one year in twelve equal monthly installments, commencing on February 6, 2021."}],"balance_after":10000,"derivative":{"exercise_price":66.49,"expiration_date":"2031-01-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001179110-21-000464","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000117911021000464/edgar.xml","form_type":"4"}},{"id":2912635,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-08T22:09:36.000Z","date":"2021-01-06","kind":"grant","acquired":true,"shares":1650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units (\"RSUs\") granted on January 6, 2021 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 8, 2021 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 6, 2022."}],"balance_after":27936,"source":{"system":"sec-edgar","filing":"0001179110-21-000464","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000117911021000464/edgar.xml","form_type":"4"}},{"id":2948178,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-11T21:12:26.000Z","date":"2020-12-09","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3 of the total number of shares subject to the option vest and become exercisable on each anniversary of December 9, 2020 (the \"Vesting Commencement Date\"), such that all of the shares subject to the option shall become vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":12.82,"expiration_date":"2030-12-08","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-20-063106","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000120919120063106/doc4.xml","form_type":"4"}},{"id":3103963,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-20T01:31:43.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":3037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":3037,"derivative":{"underlying":"Common Stock","underlying_shares":3037},"source":{"system":"sec-edgar","filing":"0000899243-20-017315","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924320017315/doc4.xml","form_type":"4"}},{"id":3103962,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-20T01:31:43.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":5247,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 17, 2020 for 11 months and the remaining 1/12th on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":5247,"derivative":{"exercise_price":64.75,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":5247},"source":{"system":"sec-edgar","filing":"0000899243-20-017315","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924320017315/doc4.xml","form_type":"4"}},{"id":3103961,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-20T01:31:43.000Z","date":"2020-06-17","kind":"exercise","acquired":true,"shares":4800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs vested in a single installment on June 17, 2020, the date of the Issuer's annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs vested in a single installment on June 17, 2020, the date of the Issuer's annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4800},"source":{"system":"sec-edgar","filing":"0000899243-20-017315","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924320017315/doc4.xml","form_type":"4"}},{"id":3103960,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-20T01:31:43.000Z","date":"2020-06-19","kind":"sale","acquired":false,"shares":881,"price":64.4154,"value":56749.9674,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of Issuer's Common Stock sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2020, for the Reporting Person's taxes in connection with the vesting of 4,800 shares of Common Stock underlying the Reporting Person's RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents weighted average sales price. The shares were sold at prices ranging from $64.24 to $64.60. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":2256,"source":{"system":"sec-edgar","filing":"0000899243-20-017315","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924320017315/doc4.xml","form_type":"4"}},{"id":3103959,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-20T01:31:43.000Z","date":"2020-06-19","kind":"sale","acquired":false,"shares":1663,"price":63.6881,"value":105913.3103,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of Issuer's Common Stock sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2020, for the Reporting Person's taxes in connection with the vesting of 4,800 shares of Common Stock underlying the Reporting Person's RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents weighted average sales price. The shares were sold at prices ranging from $63.23 to $63.88. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":3137,"source":{"system":"sec-edgar","filing":"0000899243-20-017315","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924320017315/doc4.xml","form_type":"4"}},{"id":3103958,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-20T01:31:43.000Z","date":"2020-06-17","kind":"exercise","acquired":true,"shares":4800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":4800,"source":{"system":"sec-edgar","filing":"0000899243-20-017315","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924320017315/doc4.xml","form_type":"4"}},{"id":3112206,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-12T20:04:20.000Z","date":"2020-06-11","kind":"sale","acquired":false,"shares":364,"price":48.36,"value":17603.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 687 RSUs from a January 29, 2020 grant of 1,650 RSUs."}],"balance_after":26286,"source":{"system":"sec-edgar","filing":"0001070081-20-000110","document":"wf-form4_159199224142223.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000107008120000110/wf-form4_159199224142223.xml","form_type":"4"}},{"id":3126404,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-02T21:17:30.000Z","date":"2020-06-01","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to\nthe Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year\nanniversary of the grant date."}],"balance_after":10000,"derivative":{"exercise_price":13.11,"expiration_date":"2030-05-31","underlying":"Common Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-033639","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000120919120033639/doc4.xml","form_type":"4"}},{"id":3296954,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right To Buy)","published_at":"2020-01-31T21:36:50.000Z","date":"2020-01-29","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 29, 2020 and vests over one year in twelve equal monthly installments, commencing on February 29, 2020."}],"balance_after":10000,"derivative":{"exercise_price":51.16,"expiration_date":"2030-01-28","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001070081-20-000042","document":"wf-form4_158050659169257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000107008120000042/wf-form4_158050659169257.xml","form_type":"4"}},{"id":3296953,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-31T21:36:50.000Z","date":"2020-01-29","kind":"grant","acquired":true,"shares":1650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units (\"RSUs\") granted on January 29, 2020 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 10, 2020 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 29, 2021."}],"balance_after":26650,"source":{"system":"sec-edgar","filing":"0001070081-20-000042","document":"wf-form4_158050659169257.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000107008120000042/wf-form4_158050659169257.xml","form_type":"4"}},{"id":3410523,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-09-18T23:44:10.000Z","date":"2019-09-16","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":9.44,"expiration_date":"2029-09-15","underlying":"Common Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-19-050169","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000120919119050169/doc4.xml","form_type":"4"}},{"id":3482176,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-06-20T20:02:14.000Z","date":"2019-06-18","kind":"grant","acquired":true,"shares":4800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":4800,"derivative":{"underlying":"Common Stock","underlying_shares":4800},"source":{"system":"sec-edgar","filing":"0000899243-19-017618","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924319017618/doc4.xml","form_type":"4"}},{"id":3482175,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-20T20:02:14.000Z","date":"2019-06-18","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 18, 2019, for 11 months and the remaining 1/12th on the earlier of (i) June 18, 2020 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors.  This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":7500,"derivative":{"exercise_price":56.3,"expiration_date":"2029-06-17","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000899243-19-017618","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924319017618/doc4.xml","form_type":"4"}},{"id":3688333,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-24T22:50:51.000Z","date":"2019-01-22","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 22, 2019 and vests over one year in twelve equal monthly installments, commencing on February 22, 2019."}],"balance_after":14000,"derivative":{"exercise_price":33.02,"expiration_date":"2029-01-21","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001104659-19-003204","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000110465919003204/a4.xml","form_type":"4"}},{"id":3720564,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-12-21T23:54:28.000Z","date":"2018-12-19","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest and become exercisable in 36 equal monthly installments with the first installment on January 19, 2019, subject to the recipient's continued service on the Issuer's Board of Directors.  This option is subject to accelerated vesting upon a change of control of the Issuer."}],"balance_after":30000,"derivative":{"exercise_price":38.68,"expiration_date":"2028-12-18","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-18-031625","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000089924318031625/doc4.xml","form_type":"4"}},{"id":3720897,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-12-21T12:48:34.000Z","date":"2018-12-21","kind":"disposition_to_issuer","acquired":false,"shares":19500,"price":13.19,"value":257205.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This Company stock option was scheduled to vest 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This Company stock option was scheduled to vest 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":10.81,"expiration_date":"2028-05-03","underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0001104659-18-074343","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000110465918074343/a4.xml","form_type":"4"}},{"id":3720896,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-12-21T12:48:34.000Z","date":"2018-12-21","kind":"disposition_to_issuer","acquired":false,"shares":22500,"price":13.19,"value":296775.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This Company stock option was scheduled to vest 1/3 on the business day before each of the Company's three annual stockholder meetings following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This Company stock option was scheduled to vest 1/3 on the business day before each of the Company's three annual stockholder meetings following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":10.81,"expiration_date":"2028-05-03","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001104659-18-074343","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000110465918074343/a4.xml","form_type":"4"}},{"id":3720895,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-21T12:48:34.000Z","date":"2018-12-21","kind":"disposition_to_issuer","acquired":false,"shares":3300,"price":24,"value":79200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This RSU award provided for vesting and settlement 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-18-074343","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000110465918074343/a4.xml","form_type":"4"}},{"id":3720894,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-21T12:48:34.000Z","date":"2018-12-21","kind":"disposition_to_issuer","acquired":false,"shares":3750,"price":24,"value":90000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This restricted stock unit (\"RSU\") award provided for vesting and settlement 1/3 on the business day before each of the Company's three annual stockholder meetings following May 3, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the \"Merger Agreement\"), by and among Endocyte, Inc. (the \"Company\"), Novartis AG (\"Novartis\") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis (\"Merger Sub\"), at the effective time (the \"Effective Time\") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-18-074343","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000110465918074343/a4.xml","form_type":"4"}},{"id":3904430,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-05T20:41:43.000Z","date":"2018-06-04","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and the balance of the total shares subject to the Option shall vest on the three year anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":6.2,"expiration_date":"2028-06-03","underlying":"Common Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001171843-18-004460","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000117184318004460/formfour.xml","form_type":"4"}},{"id":3945386,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-05-04T17:03:34.000Z","date":"2018-05-03","kind":"grant","acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents (i) 19,500 options that will vest on the business day prior to the next annual stockholder meeting following date of grant and (ii) 22,500 options that will vest in three installments, with 1/3 vesting on the business day before each of the Issuer's three annual stockholder meetings following the date of grant."}],"balance_after":42000,"derivative":{"exercise_price":10.81,"expiration_date":"2028-05-03","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001179110-18-006311","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000117911018006311/edgar.xml","form_type":"4"}},{"id":3945385,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-04T17:03:34.000Z","date":"2018-05-03","kind":"grant","acquired":true,"shares":7050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents (i) 3,750 restricted stock units (\"RSUs\"), granted upon election to the Issuer's Board of Directors, in which 1/3 of the total RSUs will vest on the business day before each of the Issuer's three annual stockholder meetings following the date of grant and (ii) 3,300 RSUs that will vest 100% on the business day prior to the next annual stockholder meeting following the date of grant. Each RSU will be paid in the form of one share of common stock for each RSU."}],"balance_after":7050,"source":{"system":"sec-edgar","filing":"0001179110-18-006311","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000117911018006311/edgar.xml","form_type":"4"}},{"id":4105895,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right To Buy)","published_at":"2018-01-05T21:14:29.000Z","date":"2018-01-03","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 3, 2018 and vests over one year in twelve equal monthly installments, commencing on February 3, 2018."}],"balance_after":14000,"derivative":{"exercise_price":18.01,"expiration_date":"2028-01-02","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001070081-18-000021","document":"wf-form4_151518685616516.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000107008118000021/wf-form4_151518685616516.xml","form_type":"4"}},{"id":4233587,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2017-08-15T20:54:27.000Z","date":"2017-08-14","kind":"purchase","acquired":true,"shares":50000,"price":2.8154,"value":140770.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $2.80 to $2.85, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001171843-17-005101","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000117184317005101/formfour.xml","form_type":"4"}},{"id":4295124,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-02T20:51:28.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and the balance of the total shares subject to the Option shall vest on the three year anniversary of the grant date."}],"balance_after":3500,"derivative":{"exercise_price":3.85,"expiration_date":"2027-05-31","underlying":"Common Shares","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001171843-17-003440","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000117184317003440/formfour.xml","form_type":"4"}},{"id":4306842,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-24T20:17:53.000Z","date":"2017-05-23","kind":"purchase","acquired":true,"shares":25000,"price":13.4892,"value":337230.0,"ownership":{"direct":true},"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001070081-17-000088","document":"wf-form4_149565705820885.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000107008117000088/wf-form4_149565705820885.xml","form_type":"4"}},{"id":4499406,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right To Buy)","published_at":"2017-01-06T00:23:52.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 3, 2017 and vests over one year in twelve equal monthly installments, commencing on February 3, 2017."}],"balance_after":12000,"derivative":{"exercise_price":11.23,"expiration_date":"2027-01-02","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001070081-17-000036","document":"wf-form4_148366221909135.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000107008117000036/wf-form4_148366221909135.xml","form_type":"4"}},{"id":4592176,"issuer":{"id":181987,"kind":"organization","name":"MEDIVATION, INC.","symbol":"MDVN"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2016-09-30T17:55:28.000Z","date":"2016-09-28","kind":"disposition_to_issuer","acquired":false,"shares":6228,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":58.89,"expiration_date":"2026-06-22","underlying":"Common Stock","underlying_shares":6228},"source":{"system":"sec-edgar","filing":"0001209191-16-143391","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1011835/000120919116143391/doc4.xml","form_type":"4"}},{"id":4592175,"issuer":{"id":181987,"kind":"organization","name":"MEDIVATION, INC.","symbol":"MDVN"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2016-09-30T17:55:28.000Z","date":"2016-09-28","kind":"disposition_to_issuer","acquired":false,"shares":6284,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":55.45,"expiration_date":"2025-06-16","underlying":"Common Stock","underlying_shares":6284},"source":{"system":"sec-edgar","filing":"0001209191-16-143391","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1011835/000120919116143391/doc4.xml","form_type":"4"}},{"id":4592174,"issuer":{"id":181987,"kind":"organization","name":"MEDIVATION, INC.","symbol":"MDVN"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2016-09-30T17:55:28.000Z","date":"2016-09-28","kind":"disposition_to_issuer","acquired":false,"shares":11046,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":44.815,"expiration_date":"2024-10-15","underlying":"Common Stock","underlying_shares":11046},"source":{"system":"sec-edgar","filing":"0001209191-16-143391","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1011835/000120919116143391/doc4.xml","form_type":"4"}},{"id":4592173,"issuer":{"id":181987,"kind":"organization","name":"MEDIVATION, INC.","symbol":"MDVN"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2016-09-30T17:55:28.000Z","date":"2016-09-28","kind":"disposition_to_issuer","acquired":false,"shares":9584,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":38.8863,"expiration_date":"2024-06-27","underlying":"Common Stock","underlying_shares":9584},"source":{"system":"sec-edgar","filing":"0001209191-16-143391","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1011835/000120919116143391/doc4.xml","form_type":"4"}},{"id":4592172,"issuer":{"id":181987,"kind":"organization","name":"MEDIVATION, INC.","symbol":"MDVN"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2016-09-30T17:55:28.000Z","date":"2016-09-28","kind":"disposition_to_issuer","acquired":false,"shares":12232,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":24.6,"expiration_date":"2023-06-28","underlying":"Common Stock","underlying_shares":12232},"source":{"system":"sec-edgar","filing":"0001209191-16-143391","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1011835/000120919116143391/doc4.xml","form_type":"4"}},{"id":4592171,"issuer":{"id":181987,"kind":"organization","name":"MEDIVATION, INC.","symbol":"MDVN"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2016-09-30T17:55:28.000Z","date":"2016-09-28","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":26.355,"expiration_date":"2023-04-30","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-16-143391","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1011835/000120919116143391/doc4.xml","form_type":"4"}},{"id":4592170,"issuer":{"id":181987,"kind":"organization","name":"MEDIVATION, INC.","symbol":"MDVN"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-09-30T17:55:28.000Z","date":"2016-09-28","kind":"other","acquired":false,"shares":21206,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation (\"Parent\"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (\"Purchaser\"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes 2,972 unvested shares subject to a restricted stock award."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation (\"Parent\"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (\"Purchaser\"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-16-143391","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1011835/000120919116143391/doc4.xml","form_type":"4"}},{"id":4593946,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":2603,"kind":"person","name":"Svoronos Dawn","position":1,"cik":"0001574579","reported_name":"Svoronos Dawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-09-27T23:03:22.000Z","date":"2016-09-27","kind":"grant","acquired":true,"shares":5144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and the balance of the total shares subject to the Option shall vest on the three year anniversary of the grant date."}],"balance_after":5144,"derivative":{"exercise_price":8.15,"expiration_date":"2026-09-26","underlying":"Common Shares","underlying_shares":5144},"source":{"system":"sec-edgar","filing":"0001171843-16-012294","document":"f4_svoronos092716.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574579/000117184316012294/f4_svoronos092716.xml","form_type":"4"}}]}